本帖最后由 老马 于 2012-1-13 21:20 编辑
2 O- G6 O6 c: k% H7 ]. Y5 c, e+ ]
7 Z1 _- K! H0 ]* C8 b9 K* b爱必妥和阿瓦斯丁的比较
. o; X2 U5 ~, W0 w1 `1 P
* e$ [7 _' V8 C
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% N+ K3 r8 V8 ?" l% m
$ C7 a+ \* u, k A5 Q5 H5 U
& {8 m2 E% F1 R* g5 {9 v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 P* Y( V4 X: J7 d/ E1 Q6 n
==================================================
2 T( |& R- s3 F. ]3 K- V' _" ROverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 D1 _0 r+ O0 G5 G+ zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 i5 `) a2 ]; E" {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& y7 b- R4 J1 P4 y% \$ z2 D9 j
|
显身卡
